George AL: Molecular and genetic basis of sudden cardiac death. J Clin Invest 2013;123:75.
Grant AO: Cardiac ion channels. Circ Arrhythmia Electrophysiol 2009;2:185.
Hondeghem LM: Relative contributions of TRIaD and QT to proarrhythmia. J Cardiovasc Electrophysiol 2007;18:655.
Kolettis TM: Coronary artery disease and ventricular arrhythmias: Pathophysiology and treatment. Curr Opin Pharm 2013;13:210.
Li A, Behr ER: Advances in the management of atrial fibrillation. Clin Med 2012;12:544.
Marrus SB, Nerbonne JM: Mechanisms linking shortand long-term electrical remodeling in the heart … Is it a stretch? Channels 2008;2:117.
McPhail GL, Clancy JP: Ivacaftor: The first therapy acting on the primary cause of cystic fibrosis. Drugs Today 2013;49:253.
Mohler PJ, Gramolini AO, Bennett V: Ankyrins. J Cell Biol 2002;115:1565.
Monfredi O, Maltsev VA, Lakatta EG: Modern concepts concerning the origin of the heartbeat. Physiology 2013;28:74.
Morady F: Catheter ablation of supraventricular arrhythmias: State of the art. J Cardiovasc Electrophysiol 2004;15:124.
Roubille F, Tardif J-C: New therapeutic targets in cardiology, heart failure and arrhythmia: HCN channels. Circulation 2013;127:1986.
Starmer FC, Grant AO, Strauss HC: Mechanisms of use-dependent block of sodium channels in excitable membranes by local anesthetics. Biophys J 1984;46:15.
Tradtrantip L, Namkung W, Verkman AS: Crofelemer, an antisecretory antidiarrheal proanthocyandin oligomer extracted from Croton lechleri, targets two distinct intestinal chloride channels. Mol Pharmacol 2010;77:69.
Veerakul G, Nademanec K: Brugada syndrome: Two decades of progress. Circ J 2012;76:2713.
Vizzardi E et al: A focus on antiarrhythmic properties of ranolazine. J Cardiovasc Pharm Ther 2012;17:353.
Wehrens XHT, Lehnart SE, Marks AR: Ryanodine receptor-targeted anti-arrhythmic therapy. NY Acad Sci 2005;1047:366.
Wolbrette D et al: Dronedarone for the treatment of atrial fibrillation and atrial flutter: Approval and efficacy. Vasc Health Risk Manag 2010;6:517.